Anupam Rama
Stock Analyst at JP Morgan
(3.37)
# 913
Out of 4,893 analysts
262
Total ratings
42.33%
Success rate
4.79%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Anupam Rama
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Maintains: Overweight | $30 → $28 | $19.01 | +47.29% | 13 | Jul 10, 2025 | |
| COGT Cogent Biosciences | Maintains: Overweight | $25 → $29 | $10.86 | +167.03% | 6 | Jul 10, 2025 | |
| IDYA IDEAYA Biosciences | Maintains: Overweight | $63 → $66 | $22.80 | +189.47% | 8 | May 22, 2025 | |
| OLMA Olema Pharmaceuticals | Maintains: Overweight | $30 → $28 | $4.87 | +474.95% | 4 | Mar 28, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $104 → $117 | $31.13 | +275.84% | 3 | Mar 27, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $183 → $184 | $134.93 | +36.37% | 17 | Mar 26, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $44 → $50 | $46.32 | +7.96% | 9 | Mar 24, 2025 | |
| SNDX Syndax Pharmaceuticals | Maintains: Overweight | $39 → $41 | $9.81 | +317.94% | 10 | Mar 20, 2025 | |
| ZLAB Zai Lab | Maintains: Overweight | $44 → $51 | $34.09 | +49.60% | 12 | Mar 13, 2025 | |
| SLDB Solid Biosciences | Maintains: Overweight | $12 → $11 | $5.44 | +102.21% | 7 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $34 | $7.19 | +372.88% | 4 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $42 | $26.13 | +60.73% | 11 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $77 → $71 | $24.34 | +191.70% | 9 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $54 | $19.55 | +176.29% | 16 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $44 | $16.49 | +166.83% | 4 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $18 | $10.83 | +66.28% | 8 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $21 → $22 | $11.44 | +92.31% | 4 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $15.61 | +92.18% | 1 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $17 | $6.31 | +169.63% | 13 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $8.67 | - | 7 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $40 | $28.94 | +38.22% | 3 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $125 | $81.98 | +52.48% | 6 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $5.24 | - | 1 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $12 → $10 | $9.20 | +8.70% | 7 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.40 | - | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $2.62 | - | 3 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $2.80 | +365.12% | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $9 | $0.37 | +2,331.78% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $4.48 | - | 6 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $0.38 | - | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $250 | $9.54 | +2,521.92% | 7 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.39 | - | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $58 | $36.67 | +58.17% | 1 | Dec 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 → $12 | $11.47 | +4.62% | 2 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $29 → $37 | $5.98 | +518.73% | 6 | Oct 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $55 | $52.78 | +4.21% | 3 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $1.53 | +1,736.07% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $54 | $39.68 | +36.09% | 10 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $0.38 | +11,649.35% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $27 | $8.80 | +206.99% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $10.23 | +291.20% | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $133 → $137 | $322.30 | -57.49% | 9 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $39 | $4.53 | +760.93% | 1 | Dec 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $48 | $7.64 | +528.27% | 5 | Jul 12, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $10.90 | - | 2 | May 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $18 | $0.88 | +1,945.45% | 2 | Mar 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $0.91 | +3,214.55% | 1 | Dec 4, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $49.51 | - | 2 | Nov 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.78 | - | 2 | Jul 21, 2017 |
Sarepta Therapeutics
Jul 10, 2025
Maintains: Overweight
Price Target: $30 → $28
Current: $19.01
Upside: +47.29%
Cogent Biosciences
Jul 10, 2025
Maintains: Overweight
Price Target: $25 → $29
Current: $10.86
Upside: +167.03%
IDEAYA Biosciences
May 22, 2025
Maintains: Overweight
Price Target: $63 → $66
Current: $22.80
Upside: +189.47%
Olema Pharmaceuticals
Mar 28, 2025
Maintains: Overweight
Price Target: $30 → $28
Current: $4.87
Upside: +474.95%
Ultragenyx Pharmaceutical
Mar 27, 2025
Maintains: Overweight
Price Target: $104 → $117
Current: $31.13
Upside: +275.84%
Neurocrine Biosciences
Mar 26, 2025
Maintains: Overweight
Price Target: $183 → $184
Current: $134.93
Upside: +36.37%
BridgeBio Pharma
Mar 24, 2025
Maintains: Overweight
Price Target: $44 → $50
Current: $46.32
Upside: +7.96%
Syndax Pharmaceuticals
Mar 20, 2025
Maintains: Overweight
Price Target: $39 → $41
Current: $9.81
Upside: +317.94%
Zai Lab
Mar 13, 2025
Maintains: Overweight
Price Target: $44 → $51
Current: $34.09
Upside: +49.60%
Solid Biosciences
Mar 13, 2025
Maintains: Overweight
Price Target: $12 → $11
Current: $5.44
Upside: +102.21%
Mar 5, 2025
Maintains: Overweight
Price Target: $39 → $34
Current: $7.19
Upside: +372.88%
Mar 5, 2025
Maintains: Overweight
Price Target: $36 → $42
Current: $26.13
Upside: +60.73%
Mar 4, 2025
Maintains: Overweight
Price Target: $77 → $71
Current: $24.34
Upside: +191.70%
Mar 4, 2025
Maintains: Overweight
Price Target: $50 → $54
Current: $19.55
Upside: +176.29%
Feb 26, 2025
Maintains: Overweight
Price Target: $42 → $44
Current: $16.49
Upside: +166.83%
Feb 26, 2025
Maintains: Overweight
Price Target: $16 → $18
Current: $10.83
Upside: +66.28%
Feb 26, 2025
Maintains: Overweight
Price Target: $21 → $22
Current: $11.44
Upside: +92.31%
Feb 25, 2025
Initiates: Overweight
Price Target: $30
Current: $15.61
Upside: +92.18%
Nov 12, 2024
Maintains: Overweight
Price Target: $16 → $17
Current: $6.31
Upside: +169.63%
Nov 11, 2024
Downgrades: Underweight
Price Target: n/a
Current: $8.67
Upside: -
Nov 5, 2024
Maintains: Overweight
Price Target: $39 → $40
Current: $28.94
Upside: +38.22%
Oct 4, 2024
Maintains: Overweight
Price Target: $100 → $125
Current: $81.98
Upside: +52.48%
Sep 30, 2024
Initiates: Neutral
Price Target: n/a
Current: $5.24
Upside: -
Aug 6, 2024
Maintains: Neutral
Price Target: $12 → $10
Current: $9.20
Upside: +8.70%
May 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.40
Upside: -
Apr 22, 2024
Upgrades: Neutral
Price Target: n/a
Current: $2.62
Upside: -
Apr 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $2.80
Upside: +365.12%
Aug 16, 2023
Maintains: Neutral
Price Target: $8 → $9
Current: $0.37
Upside: +2,331.78%
Jul 25, 2023
Downgrades: Underweight
Price Target: n/a
Current: $4.48
Upside: -
Nov 10, 2022
Downgrades: Underweight
Price Target: n/a
Current: $0.38
Upside: -
Jul 13, 2022
Downgrades: Neutral
Price Target: $250
Current: $9.54
Upside: +2,521.92%
Mar 8, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.39
Upside: -
Dec 10, 2021
Initiates: Overweight
Price Target: $58
Current: $36.67
Upside: +58.17%
Nov 5, 2021
Upgrades: Neutral
Price Target: $7 → $12
Current: $11.47
Upside: +4.62%
Oct 25, 2021
Upgrades: Neutral
Price Target: $29 → $37
Current: $5.98
Upside: +518.73%
Oct 12, 2021
Upgrades: Overweight
Price Target: $55
Current: $52.78
Upside: +4.21%
Aug 10, 2021
Initiates: Overweight
Price Target: $28
Current: $1.53
Upside: +1,736.07%
Mar 1, 2021
Downgrades: Neutral
Price Target: $54
Current: $39.68
Upside: +36.09%
Jan 11, 2021
Initiates: Overweight
Price Target: $45
Current: $0.38
Upside: +11,649.35%
Oct 12, 2020
Initiates: Overweight
Price Target: $27
Current: $8.80
Upside: +206.99%
Aug 18, 2020
Initiates: Overweight
Price Target: $40
Current: $10.23
Upside: +291.20%
May 7, 2020
Downgrades: Neutral
Price Target: $133 → $137
Current: $322.30
Upside: -57.49%
Dec 24, 2019
Initiates: Overweight
Price Target: $39
Current: $4.53
Upside: +760.93%
Jul 12, 2019
Downgrades: Neutral
Price Target: $29 → $48
Current: $7.64
Upside: +528.27%
May 10, 2018
Upgrades: Overweight
Price Target: n/a
Current: $10.90
Upside: -
Mar 6, 2018
Maintains: Overweight
Price Target: $15 → $18
Current: $0.88
Upside: +1,945.45%
Dec 4, 2017
Initiates: Overweight
Price Target: $30
Current: $0.91
Upside: +3,214.55%
Nov 16, 2017
Upgrades: Neutral
Price Target: n/a
Current: $49.51
Upside: -
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $0.78
Upside: -